DK3812392T3 - Oxysteroler og fremgangsmåder til anvendelse deraf - Google Patents

Oxysteroler og fremgangsmåder til anvendelse deraf

Info

Publication number: DK3812392T3
Authority: DK; Denmark
Prior art keywords: oxysterols; methods
Prior art date: 2015-07-06

Application number

DK20214736.9T

Other languages

English (en)

Inventor

Francesco G Salituro

Albert Jean Robichaud

Botella Gabriel Martinez

Boyd L Harrison

Original Assignee

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-07-06

Publication date

2025-07-21

2016-07-06 Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc

2025-07-21 Application granted granted Critical

2025-07-21 Publication of DK3812392T3 publication Critical patent/DK3812392T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK20214736.9T 2015-07-06 2016-07-06 Oxysteroler og fremgangsmåder til anvendelse deraf DK3812392T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562189068P	2015-07-06	2015-07-06
US201662332931P	2016-05-06	2016-05-06
EP16821926.9A EP3319612B1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3812392T3 true DK3812392T3 (da)	2025-07-21

Family

ID=57686127

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK20214736.9T DK3812392T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgangsmåder til anvendelse deraf
DK16821926.9T DK3319612T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgansmåder til anvendelse derfor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK16821926.9T DK3319612T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgansmåder til anvendelse derfor

Country Status (30)

Country	Link
US (3)	US11117924B2 (da)
EP (3)	EP3812392B1 (da)
JP (4)	JP2018519328A (da)
KR (2)	KR20180026742A (da)
CN (3)	CN113501855A (da)
AU (3)	AU2016289971C1 (da)
CA (1)	CA2991313C (da)
CO (1)	CO2018000589A2 (da)
CY (1)	CY1124620T1 (da)
DK (2)	DK3812392T3 (da)
ES (2)	ES3036110T3 (da)
FI (1)	FI3812392T3 (da)
HR (2)	HRP20250799T1 (da)
HU (2)	HUE071964T2 (da)
IL (3)	IL282048B2 (da)
LT (2)	LT3812392T (da)
MA (1)	MA54851A (da)
MD (1)	MD3319612T2 (da)
MX (3)	MX2021005052A (da)
MY (1)	MY197698A (da)
PE (1)	PE20180482A1 (da)
PH (2)	PH12020551586A1 (da)
PL (2)	PL3319612T3 (da)
PT (2)	PT3812392T (da)
RS (2)	RS66996B1 (da)
RU (1)	RU2742333C2 (da)
SG (1)	SG10202002655VA (da)
SI (2)	SI3812392T1 (da)
SM (2)	SMT202500264T1 (da)
WO (1)	WO2017007840A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107936076B (zh)	2011-09-08	2021-10-15	萨奇治疗股份有限公司	神经活性类固醇、组合物、及其用途
MX362544B (es)	2013-03-13	2019-01-24	Sage Therapeutics Inc	Esteroides neuroactivos y metodos para su uso.
EP4306114A1 (en)	2014-06-18	2024-01-17	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
PL3319612T3 (pl) *	2015-07-06	2021-12-20	Sage Therapeutics, Inc.	Oksysterole i sposoby ich stosowania
EP3828194B1 (en)	2015-07-06	2025-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
HK1255500A1 (zh) *	2015-07-06	2019-08-16	Sage Therapeutics, Inc.	氧固醇及其使用方法
US20190330259A1 (en)	2016-04-01	2019-10-31	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
MD3481846T2 (ro)	2016-07-07	2021-11-30	Sage Therapeutics Inc	24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CN121085986A (zh)	2016-09-30	2025-12-09	萨奇治疗股份有限公司	C7取代的氧固醇及其作为nmda调节剂的方法
TW202444381A (zh)	2016-10-18	2024-11-16	美商賽吉醫療公司	氧固醇(oxysterol)及其使用方法
KR102521573B1 (ko)	2016-10-18	2023-04-14	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN113121631B (zh) *	2021-03-25	2023-02-03	西北农林科技大学	一种羊毛甾烷灵芝三萜类化合物、制备方法及应用
AU2022291395A1 (en)	2021-06-11	2024-01-04	Sage Therapeutics, Inc.	Neuroactive steroid for the treatment of alzheimer's disease
WO2023114224A1 (en)	2021-12-13	2023-06-22	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025020191A1 (zh) *	2023-07-27	2025-01-30	珂阑(上海)医药科技有限公司	甾类化合物、其制备方法和应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2259698A (en)	1938-05-07	1941-10-21	Rare Chemicals Inc	Physiologically effective substance and process of preparing same
US2594323A (en)	1948-07-22	1952-04-29	Upjohn Co	24-substituted delta 5-cholene-3, 24-diols
US2673206A (en)	1950-06-07	1954-03-23	Schering Corp	25-ethinyl steroids
US3079385A (en)	1961-01-24	1963-02-26	Roussel Uclaf	Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
JPS5324071B2 (da)	1974-04-30	1978-07-18
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en)	1975-10-10	1982-03-31	Hoffmann La Roche	Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja)	1976-12-28	1983-09-08	帝人株式会社	ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en)	1977-07-18	1980-01-15	Kaiser Emil T	Process for preparing 25-hydroxycholesterol
JPS54163565A (en)	1978-06-09	1979-12-26	Teijin Ltd	24255epoxyy3beta 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en)	1978-08-01	1979-11-13	Kaiser Emil T	Synthesis of steroids
US4269777A (en)	1979-05-21	1981-05-26	Wisconsin Alumni Research Foundation	Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en)	1980-08-13	1982-02-26	Teijin Ltd	25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja)	1985-05-07	1986-11-12	Sumitomo Pharmaceut Co Ltd	コレステロ−ルのフツ素誘導体
ATE45347T1 (de)	1985-05-30	1989-08-15	Taisho Pharmaceutical Co Ltd	Vitamin d3-derivate.
JPS62187485A (ja)	1986-02-13	1987-08-15	Teijin Ltd	２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0701444B1 (en)	1993-05-24	2010-04-07	Purdue Pharma Ltd.	Methods and compositions for inducing sleep
IL110309A0 (en)	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
PT752860E (pt)	1994-02-14	2000-12-29	Euro Celtique Sa	Androstanos e pregnanos para modulacao alosterica do receptor de gaba
TW385308B (en)	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en)	1994-10-25	1997-01-21	Merck & Co., Inc.	7-substituted 4-aza cholanic acid derivatives and their use
CN1171114A (zh)	1994-11-23	1998-01-21	科斯赛斯公司	用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
JPH08268917A (ja)	1995-03-31	1996-10-15	D D S Kenkyusho:Kk	癌組織への移行性の高い制癌剤
US6780853B1 (en) *	1995-06-06	2004-08-24	Euro-Celtique S.A.	Neuroactive steroids of the androstane and pregnane series
CA2223996A1 (en)	1995-06-06	1996-12-19	Cocensys, Inc.	Neuroactive steroids of the androstane and pregnane series
US5792635A (en)	1995-06-07	1998-08-11	Magainin Pharmaceuticals, Inc.	Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
ATE254628T1 (de)	1995-06-23	2003-12-15	Novo Nordisk As	Meiose regulierende verbindungen.
US6645953B2 (en)	1995-06-23	2003-11-11	Novo Nordisk A/S	Meiosis regulating compounds
WO1997003677A1 (en)	1995-07-24	1997-02-06	Trustees Of Boston University	Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en)	1995-07-26	1999-03-30	Trustees Of Boston University	Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997042215A1 (en)	1996-05-06	1997-11-13	Bionumerik Pharmaceuticals, Inc.	Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja)	1996-06-10	1997-12-22	Teijin Ltd	２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en)	1996-08-01	1998-02-12	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6122371A (en)	1997-07-22	2000-09-19	Atwell; Ronald C.	Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en)	1998-05-11	1999-11-18	Novo Nordisk A/S	Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko)	1998-05-13	2001-05-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	감수분열 조절 화합물
US8541600B2 (en) *	1998-11-24	2013-09-24	Harbor Therapeutics, Inc.	11-aza, 11-thia and 11-oxa sterol compounds and compositions
US6376530B1 (en)	1999-05-10	2002-04-23	Merck & Co., Inc.	Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en)	1999-05-11	1999-07-14	Res Inst Medicine Chem	Chemical compounds
CN1111167C (zh)	1999-10-22	2003-06-11	中国科学院上海有机化学研究所	3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh)	1999-11-12	2003-01-08	中国科学院上海有机化学研究所	高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en)	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
GB0019290D0 (en)	2000-08-04	2000-09-27	Symphar Sa	Methods for inducing apolipoprotein E secretion
GR1003861B (el)	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en)	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en)	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
DK1392713T3 (da)	2001-05-03	2008-02-18	Univ Chicago	Lever-X-receptoragonister
JP2005508368A (ja)	2001-11-08	2005-03-31	ザユニバーシティーオブシカゴ	高コレステロール濃度に関連した疾患の治療方法
CA2468989A1 (en)	2001-12-07	2003-06-19	Daniel M. Schwartz	Treatment for age-related macular degeneration
KR101130212B1 (ko)	2002-03-27	2012-04-13	파이토팜 피엘씨	사포게닌 및 그 유도체의 치료 방법 및 사용법
NZ547344A (en)	2002-03-27	2007-11-30	Phytopharm Plc	Therapeutic methods and uses of sapogenins and their derivatives
GB0216621D0 (en)	2002-07-17	2002-08-28	Imaging Res Solutions Ltd	Imaging compounds
US6933312B2 (en)	2002-10-07	2005-08-23	Agouron Pharmaceuticals, Inc.	Pyrazole derivatives
CA2506568A1 (en)	2002-11-22	2004-06-10	Merck & Co., Inc.	2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003288231A1 (en)	2002-12-13	2004-07-09	Bayer Healthcare Ag	Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr)	2003-01-17	2007-04-06	Mapreg	Medicaments pour le systeme nerveux
GB0403889D0 (en)	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
US8604011B2 (en)	2004-09-27	2013-12-10	The Regents Of The University Of California	Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en)	2004-10-08	2007-02-08	Shutsung Liao	Methods of treating cancers
CA2585471A1 (en)	2004-11-01	2006-05-11	Seo Hong Yoo	Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
CA2643732C (en)	2006-02-27	2012-08-21	The Regents Of The University Of California	Oxysterol compounds and the hedgehog pathway
CN101164540A (zh)	2006-08-03	2008-04-23	中山大学	海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en)	2006-10-06	2006-11-15	Birkeland Innovasjon As	Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en)	2006-11-02	2008-05-15	Curis, Inc.	Small organic molecule regulators of cell proliferation
EP2097437B1 (en)	2006-11-21	2015-05-27	Umecrine Cognition AB	The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
JP5587184B2 (ja)	2007-06-20	2014-09-10	オースペックス・ファーマシューティカルズ・インコーポレイテッド	繊維症阻害剤としての置換ｎ−アリールピリジノン
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
WO2009059961A2 (en)	2007-11-06	2009-05-14	N.V. Organon	A method of hormone suppression in humans
JP2011505357A (ja)	2007-12-03	2011-02-24	ザリージェンツオブザユニバーシティーオブカリフォルニア	ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en)	2008-01-16	2009-07-23	Jado Technologies Gmbh	Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
AU2009206580A1 (en)	2008-01-25	2009-07-30	Merck Sharp & Dohme Corp.	Quinolizidinone M1 receptor positive allosteric modulators
US8778410B2 (en) *	2008-02-19	2014-07-15	Earnest Medicine Co., Ltd.	Oral or enteral composition useful for recovery of physical functions
US8497122B2 (en) *	2008-04-11	2013-07-30	Washington University	Biomarkers for Niemann-pick C disease and related disorders
NZ589764A (en)	2008-05-09	2012-10-26	Univ Emory	NMDA receptor antagonists for the treatment of neuropsychiatric disorders
BRPI0909564B8 (pt) *	2008-05-28	2021-05-25	Reveragen Biopharma Inc	uso de um composto
WO2010065709A2 (en)	2008-12-03	2010-06-10	Amin Khan	Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en)	2008-12-22	2010-07-01	University Of Washington	Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en)	2009-01-28	2010-08-05	Emory University	Subunit selective nmda receptor potentiators for the treatment of neurological conditions
JP2013500986A (ja)	2009-07-29	2013-01-10	ザ・ユニバーシティ・オブ・シカゴ	肝臓ｘ受容体アゴニスト
WO2011028794A2 (en)	2009-09-01	2011-03-10	Lazarus Therapeutics, Inc.	Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr)	2009-12-02	2015-10-16	Assist Publ Hopitaux Marseille	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
JP2011135864A (ja) *	2009-12-30	2011-07-14	Korea Univ Research & Business Foundation	Ｏｃｔ４及びＢｍｉ１、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en)	2010-05-14	2010-06-30	Ge Healthcare Ltd	Method of synthesis
US20120035156A1 (en)	2010-08-09	2012-02-09	Daniela Alberati	Combination of glyt1 compound with antipsychotics
US8969525B2 (en)	2010-11-09	2015-03-03	Enzo Life Sciences, Inc.	Hydroxycholesterol immunoassay
US20150031655A1 (en)	2011-04-15	2015-01-29	University Of North Dakota	Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en)	2011-05-27	2012-12-06	Cytocure Llc	Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en)	2011-07-29	2015-01-14	Univ California	NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) *	2011-09-08	2021-10-15	萨奇治疗股份有限公司	神经活性类固醇、组合物、及其用途
SG2014010417A (en)	2011-10-07	2014-06-27	Takeda Pharmaceutical	1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CN113234114A (zh)	2011-10-14	2021-08-10	萨奇治疗股份有限公司	3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en)	2012-04-25	2015-04-30	The Regents Of The University Of California	Drug screening platform for rett syndrome
US9737522B2 (en)	2012-08-09	2017-08-22	Emory University	NMDA receptor modulators and uses related thereto
WO2014028942A2 (en)	2012-08-17	2014-02-20	Trueex Group Llc	Interoffice bank offered rate financial product and implementation
CA2882870C (en) *	2012-08-24	2020-12-15	Integurx Therapeutics, Llc	Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
PT2935307T (pt)	2012-12-18	2018-07-31	Univ Washington	Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
EP3309166A3 (en)	2013-01-23	2018-08-22	Sphaera Pharma Pvt. Ltd.	11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
KR20150110787A (ko)	2013-01-29	2015-10-02	노렉스, 인크.	스피로-락탐 nmda 수용체 조절인자 및 그의 용도
JP2016514967A (ja)	2013-03-13	2016-05-26	セージセラピューティクス，インコーポレイテッド	神経刺激性ステロイド、組成物およびそれらの使用
MX362544B (es)	2013-03-13	2019-01-24	Sage Therapeutics Inc	Esteroides neuroactivos y metodos para su uso.
KR20160060688A (ko)	2013-09-25	2016-05-30	반 안델 리서치 인스티튜트	고도로 강력한 글루코코르티코이드
CN103655582B (zh) *	2013-11-30	2015-05-27	浙江大学	一种环氧甾醇组合物及制备和用途
EP4306114A1 (en)	2014-06-18	2024-01-17	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
WO2016007762A1 (en)	2014-07-09	2016-01-14	Duke University	Compositions and methods for the repair of myelin
US10016095B2 (en) *	2014-10-03	2018-07-10	Progressive International Corporation	Salad spinner
RU2764702C2 (ru)	2014-10-07	2022-01-19	Сейдж Терапьютикс, Инк.	Нейроактивные соединения и способы их применения
EP3828194B1 (en)	2015-07-06	2025-04-16	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
PL3319612T3 (pl) *	2015-07-06	2021-12-20	Sage Therapeutics, Inc.	Oksysterole i sposoby ich stosowania
HK1255500A1 (zh) *	2015-07-06	2019-08-16	Sage Therapeutics, Inc.	氧固醇及其使用方法
GB2557875A (en)	2015-09-02	2018-07-04	Univ Swansea	Diagnostic methods and kits
US20190330259A1 (en)	2016-04-01	2019-10-31	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
MD3481846T2 (ro)	2016-07-07	2021-11-30	Sage Therapeutics Inc	24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CA3030420C (en)	2016-07-11	2025-11-18	Sage Therapeutics, Inc.	C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
CN121085986A (zh)	2016-09-30	2025-12-09	萨奇治疗股份有限公司	C7取代的氧固醇及其作为nmda调节剂的方法
TW202444381A (zh)	2016-10-18	2024-11-16	美商賽吉醫療公司	氧固醇(oxysterol)及其使用方法
KR102521573B1 (ko)	2016-10-18	2023-04-14	세이지 테라퓨틱스, 인크.	옥시스테롤 및 그의 사용 방법
WO2018170336A1 (en)	2017-03-15	2018-09-20	Modernatx, Inc.	Lipid nanoparticle formulation
AU2018288883B2 (en)	2017-06-23	2022-06-02	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of bile acid derivatives
SG11202004329TA (en)	2017-11-10	2020-06-29	Marinus Pharmaceuticals Inc	Ganaxolone for use in treating genetic epileptic disoders

2016
- 2016-07-06 PL PL16821926T patent/PL3319612T3/pl unknown
- 2016-07-06 IL IL282048A patent/IL282048B2/en unknown
- 2016-07-06 ES ES20214736T patent/ES3036110T3/es active Active
- 2016-07-06 SI SI201631911T patent/SI3812392T1/sl unknown
- 2016-07-06 EP EP20214736.9A patent/EP3812392B1/en active Active
- 2016-07-06 RS RS20250662A patent/RS66996B1/sr unknown
- 2016-07-06 PH PH1/2020/551586A patent/PH12020551586A1/en unknown
- 2016-07-06 DK DK20214736.9T patent/DK3812392T3/da active
- 2016-07-06 MX MX2021005052A patent/MX2021005052A/es unknown
- 2016-07-06 CN CN202110635348.8A patent/CN113501855A/zh active Pending
- 2016-07-06 ES ES16821926T patent/ES2884086T3/es active Active
- 2016-07-06 MD MDE20180513T patent/MD3319612T2/ro unknown
- 2016-07-06 HR HRP20250799TT patent/HRP20250799T1/hr unknown
- 2016-07-06 HU HUE20214736A patent/HUE071964T2/hu unknown
- 2016-07-06 MY MYPI2018000010A patent/MY197698A/en unknown
- 2016-07-06 WO PCT/US2016/041175 patent/WO2017007840A1/en not_active Ceased
- 2016-07-06 LT LTEP20214736.9T patent/LT3812392T/lt unknown
- 2016-07-06 AU AU2016289971A patent/AU2016289971C1/en active Active
- 2016-07-06 KR KR1020187003209A patent/KR20180026742A/ko not_active Ceased
- 2016-07-06 LT LTEP16821926.9T patent/LT3319612T/lt unknown
- 2016-07-06 JP JP2017568203A patent/JP2018519328A/ja not_active Withdrawn
- 2016-07-06 PT PT202147369T patent/PT3812392T/pt unknown
- 2016-07-06 RS RS20211000A patent/RS62220B1/sr unknown
- 2016-07-06 RU RU2018104245A patent/RU2742333C2/ru active
- 2016-07-06 PE PE2018000037A patent/PE20180482A1/es unknown
- 2016-07-06 CA CA2991313A patent/CA2991313C/en active Active
- 2016-07-06 SM SM20250264T patent/SMT202500264T1/it unknown
- 2016-07-06 MX MX2018000280A patent/MX382122B/es unknown
- 2016-07-06 SG SG10202002655VA patent/SG10202002655VA/en unknown
- 2016-07-06 US US15/742,424 patent/US11117924B2/en active Active
- 2016-07-06 MX MX2020010690A patent/MX390271B/es unknown
- 2016-07-06 SM SM20210476T patent/SMT202100476T1/it unknown
- 2016-07-06 PT PT168219269T patent/PT3319612T/pt unknown
- 2016-07-06 CN CN201680050744.1A patent/CN108135911B/zh active Active
- 2016-07-06 FI FIEP20214736.9T patent/FI3812392T3/fi active
- 2016-07-06 HU HUE16821926A patent/HUE055199T2/hu unknown
- 2016-07-06 EP EP25170345.0A patent/EP4599887A3/en active Pending
- 2016-07-06 DK DK16821926.9T patent/DK3319612T3/da active
- 2016-07-06 PL PL20214736.9T patent/PL3812392T3/pl unknown
- 2016-07-06 EP EP16821926.9A patent/EP3319612B1/en active Active
- 2016-07-06 CN CN202411074416.8A patent/CN118994288A/zh active Pending
- 2016-07-06 HR HRP20211282TT patent/HRP20211282T1/hr unknown
- 2016-07-06 SI SI201631298T patent/SI3319612T1/sl unknown
- 2016-07-06 MA MA054851A patent/MA54851A/fr unknown
- 2016-07-06 KR KR1020247037600A patent/KR20240166589A/ko active Pending
2017
- 2017-12-24 IL IL256531A patent/IL256531B/en active IP Right Grant
2018
- 2018-01-05 PH PH12018500061A patent/PH12018500061A1/en unknown
- 2018-01-22 CO CONC2018/0000589A patent/CO2018000589A2/es unknown
2020
- 2020-12-24 JP JP2020215040A patent/JP2021046444A/ja not_active Withdrawn
2021
- 2021-08-06 US US17/396,034 patent/US11732000B2/en active Active
- 2021-08-13 CY CY20211100733T patent/CY1124620T1/el unknown
- 2021-08-20 AU AU2021218230A patent/AU2021218230B2/en active Active
2022
- 2022-01-19 IL IL289976A patent/IL289976B1/en unknown
- 2022-06-03 JP JP2022091046A patent/JP7602512B2/ja active Active
2023
- 2023-06-29 US US18/216,057 patent/US20240132535A1/en active Pending
2024
- 2024-01-15 AU AU2024200254A patent/AU2024200254A1/en active Pending
- 2024-12-06 JP JP2024213248A patent/JP2025026574A/ja active Pending

Also Published As

Publication number	Publication date
EP3319612A4 (en)	2019-03-06
ES2884086T3 (es)	2021-12-10
EP3319612A1 (en)	2018-05-16
RU2742333C2 (ru)	2021-02-04
EP4599887A2 (en)	2025-08-13
AU2016289971B2 (en)	2021-09-09
MX382122B (es)	2025-03-13
SMT202100476T1 (it)	2021-09-14
PT3319612T (pt)	2021-08-24
HUE071964T2 (hu)	2025-10-28
IL289976B1 (en)	2025-12-01
IL282048A (en)	2021-05-31
AU2021218230A1 (en)	2021-09-09
LT3812392T (lt)	2025-08-11
EP3319612B1 (en)	2021-05-19
DK3319612T3 (da)	2021-08-23
AU2024200254A1 (en)	2024-02-01
CN113501855A (zh)	2021-10-15
IL289976A (en)	2022-03-01
EP4599887A3 (en)	2025-10-15
ES3036110T3 (en)	2025-09-12
IL282048B1 (en)	2024-05-01
PT3812392T (pt)	2025-07-21
PL3812392T3 (pl)	2025-09-08
RS62220B1 (sr)	2021-09-30
MX2020010690A (es)	2022-02-25
MX390271B (es)	2025-03-20
JP7602512B2 (ja)	2024-12-18
CN108135911B (zh)	2021-06-25
AU2016289971A1 (en)	2018-01-25
BR112018000205A2 (pt)	2018-09-04
CY1124620T1 (el)	2022-07-22
RU2018104245A (ru)	2019-08-07
IL256531A (en)	2018-02-28
US11117924B2 (en)	2021-09-14
AU2021218230B2 (en)	2023-11-16
JP2025026574A (ja)	2025-02-21
JP2022107795A (ja)	2022-07-22
AU2016289971C1 (en)	2022-12-08
SMT202500264T1 (it)	2025-09-12
NZ777721A (en)	2024-10-25
RU2018104245A3 (da)	2019-10-31
US20220048943A1 (en)	2022-02-17
RS66996B1 (sr)	2025-08-29
US20240132535A1 (en)	2024-04-25
LT3319612T (lt)	2021-08-25
JP2021046444A (ja)	2021-03-25
JP2018519328A (ja)	2018-07-19
MA54851A (fr)	2021-12-08
SG10202002655VA (en)	2020-05-28
MX2018000280A (es)	2018-03-08
CN108135911A (zh)	2018-06-08
US20180194797A1 (en)	2018-07-12
CO2018000589A2 (es)	2018-07-10
PL3319612T3 (pl)	2021-12-20
MY197698A (en)	2023-07-06
HRP20250799T1 (hr)	2025-09-12
US11732000B2 (en)	2023-08-22
PH12020551586A1 (en)	2023-07-31
MD3319612T2 (ro)	2021-10-31
RU2021100377A (ru)	2021-05-18
NZ738849A (en)	2024-10-25
EP3812392A1 (en)	2021-04-28
PE20180482A1 (es)	2018-03-07
CA2991313C (en)	2023-12-19
WO2017007840A1 (en)	2017-01-12
CN118994288A (zh)	2024-11-22
MX2021005052A (es)	2022-10-11
HUE055199T2 (hu)	2021-11-29
IL256531B (en)	2021-04-29
SI3812392T1 (sl)	2025-09-30
CA2991313A1 (en)	2017-01-12
EP3812392B1 (en)	2025-04-16
KR20240166589A (ko)	2024-11-26
EP4599887A8 (en)	2025-09-24
FI3812392T3 (fi)	2025-07-11
PH12018500061A1 (en)	2018-07-23
SI3319612T1 (sl)	2021-11-30
IL282048B2 (en)	2024-09-01
HRP20211282T1 (hr)	2021-11-12
KR20180026742A (ko)	2018-03-13

Publication	Publication Date	Title
IL282048A (en)	2021-05-31	Oxysterols and methods of use thereof
DK3828194T3 (da)	2025-06-30	Oxysteroler og fremgangsmåder til anvendelse deraf
DK3529257T3 (da)	2023-08-07	Oxysteroler og fremgangsmåder til anvendelse deraf
DK4105223T3 (da)	2025-07-07	Oxysteroler og fremgangsmåder til anvendelse deraf
IL271025A (en)	2020-01-30	Multibiotic agents and methods of using the same
DK3353210T3 (da)	2025-01-06	Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3394065T3 (da)	2021-05-31	Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3259597T3 (da)	2022-05-09	Pvrig-polypeptider og fremgangsmåder til behandling
DK3436048T3 (da)	2025-09-15	Neoantigener og fremgangsmåder til anvendelse deraf
DK3653221T5 (da)	2024-08-26	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3209308T3 (da)	2022-10-03	Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
DK3234133T3 (da)	2021-02-08	Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3303386T3 (da)	2024-10-28	Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3285777T3 (da)	2021-08-30	Glycan-terapier og fremgangsmåder til behandling
DK3265947T3 (da)	2021-10-04	Fremgangsmåde og system til kryptering
DK3548033T3 (da)	2024-07-15	Forbindelser og deres fremgangsmåde til anvendelse
DK3339479T3 (da)	2021-10-25	Elektrolyseindretning og elektrolysefremgangsmåde
DK3250610T3 (da)	2023-10-30	Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3436022T3 (da)	2022-06-20	Oxysteroler og fremgangsmåder til anvendelse heraf
DK3240895T3 (da)	2022-04-11	Sammensætninger og fremgangsmåder til proteinglykosylering
DK3220973T3 (da)	2022-03-14	Kunstigt lungesystem og fremgangsmåder til anvendelse deraf
DK3525583T3 (da)	2025-10-27	Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3551209T3 (da)	2021-08-23	Insulin-fc-fusioner og fremgangsmåder til anvendelse